Literature DB >> 8607886

Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood.

E Hagiwara1, M F Gourley, S Lee, D K Klinman.   

Abstract

OBJECTIVE: To compare the phenotype and frequency of cells that actively secrete type 1 and type 2 cytokines in systemic lupus erythematosus (SLE) patients (n = 46), versus normal controls (n = 60).
METHODS: ELISPOT analysis of freshly isolated peripheral blood mononuclear cells (PBMC).
RESULTS: T cells were the major source of interleukin-2 (IL-2), IL-4, and interferon gamma (IFN gamma), whereas monocytes were the primary source of IL-6 and IL-10 in the PB of lupus patients. Significantly fewer PBMC spontaneously secreted IFN gamma and IL-2 (P > or = 0.03), while significantly more PBMC produced IL-6 and IL-10 (P < 0.001), in lupus patients versus controls. Disease severity in lupus patients correlated with an elevated ratio of IL-1O:IFN gamma-secreting cells (P < 0.001).
CONCLUSION: SLE is characterized by an imbalance in the ratio of type 1:type 2 cytokine-secreting PBMC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8607886     DOI: 10.1002/art.1780390305

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  62 in total

1.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  IVIg attenuates TLR-9 activation in B cells from SLE patients.

Authors:  Aharon Kessel; Regina Peri; Tharwat Haj; Ayelet Snir; Gleb Slobodin; Edmond Sabo; Itzhak Rosner; Yehuda Shoenfeld; Elias Toubi
Journal:  J Clin Immunol       Date:  2010-10-05       Impact factor: 8.317

3.  Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.

Authors:  Sander I van Leuven; Yanice V Mendez-Fernandez; Ashley J Wilhelm; Nekeithia S Wade; Curtis L Gabriel; John J Kastelein; Erik S Stroes; Paul P Tak; Amy S Major
Journal:  Ann Rheum Dis       Date:  2011-09-27       Impact factor: 19.103

Review 4.  New therapies and preventive strategies to treat and minimize damage in lupus.

Authors:  Henda Bouali; Gary Gilkeson
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

5.  Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis.

Authors:  M Aleksza; A Szegedi; P Antal-Szalmás; B Irinyi; L Gergely; A Ponyi; J Hunyadi; S Sipka; M Zeher; G Szegedi; K Dankó
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

6.  IL-21 mediates suppressive effects via its induction of IL-10.

Authors:  Rosanne Spolski; Hyoung-Pyo Kim; Wei Zhu; David E Levy; Warren J Leonard
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 7.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

Review 8.  B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases.

Authors:  William Stohl
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

Review 9.  Pathogenesis of systemic lupus erythematosus.

Authors:  C C Mok; C S Lau
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

Review 10.  B-cell-targeted therapies in systemic lupus erythematosus.

Authors:  Vera Sau-Fong Chan; Helen Hoi-Lun Tsang; Rachel Chun-Yee Tam; Liwei Lu; Chak-Sing Lau
Journal:  Cell Mol Immunol       Date:  2013-01-28       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.